主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RNAZ
#4268
TransCode Therapeutics, Inc. Common Stock
9.830
0
USD
+0.31%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
+0.31%
每月变动
+3.39%
6个月变化
+3.39%
年变化
+3.39%
前一天收盘价
9.800
0
Open
9.750
0
Bid
9.830
0
Ask
9.833
0
Low
9.750
0
High
9.830
0
交易量
9
市场
股票
医疗保健
RNAZ
Open full chart
Financials
Overview
声明
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
18.69 K
833.62 K
833.62 K
833.68 K
916.97 K
—
Valuation ratios
Enterprise value
—
—
—
-897.27 K
7.02 M
—
Price to earnings ratio
—
—
—
-0.07
0.47
—
Price to sales ratio
—
—
—
1
0.61
—
Price to cash flow ratio
—
—
—
0
0.01
—
Price to book ratio
—
—
—
0.63
-0.12
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.59
-0.81
0.92
-0.52
-0.93
-1.34
Return on equity %
-1.41
2.93
1.18
-0.7
-3.41
0.01
Return on invested capital %
-1 819.69
-5 498.91
-6 115.37
-19.33 K
-7 293.21
-38.24 K
Gross margin %
100
100
100
100
100
400
Operating margin %
1 376.48
-2 231.58
11.66 K
8 889.03
14.23 K
32.55 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 475.63
-2 592.49
-44.5 K
9 005.63
15.15 K
-22.94 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
1.58
2.56
5.2
5.27
1.6
14.62
Inventory turnover
—
—
—
—
—
—
Asset turnover
-0.04
0.04
-0
-0
-0
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1 036.75
1 846.9
18
5.04
4.92
1 874.85
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
119.55
456.03
67.34
8.88
3.4
535.65
Net current asset value per share
227.31
557.72
75.72
9.89
5.7
649.03
Tangible book value per share
103.96
-158.73
59.75
7.37
1.71
-89.89
Working capital per share
83.6
339.78
61.16
8.01
2.14
411.09
Book value per share
103.96
-158.73
59.75
7.37
1.71
-89.89
新闻
TransCode从Unleash获得膀胱癌疗法平台授权
TransCode licenses bladder cancer therapy platform from Unleash
TransCode Therapeutics股价在提交IND修正案后大涨
TransCode Therapeutics股价在有希望的胶质母细胞瘤研究后飙升
TransCode Therapeutics stock soars after promising glioblastoma study
TransCode Therapeutics appoints Jack E. Stover to board of directors
TransCode和Quantum Leap将在2a期临床试验中测试癌症疗法
TransCode and Quantum Leap to test cancer therapy in phase 2a trial
TransCode Therapeutics appoints Michel Janicot as development officer
Transcode Therapeutics修改优先股条款获股东批准
Transcode Therapeutics amends preferred stock terms following shareholder approval
TransCode reports positive safety data from TTX-MC138 phase 1a trial